Weight loss interventions and obesity-associated cancers in people with type 2 diabetes and overweight/obesity: A real-world observational study.
Ipaye. Testimony T; Goldney. Jonathan J; Wilkinson. Thomas J TJ; Zaccardi. Francesco F; Yates. Thomas T; Davies. Melanie J MJ; Brown. Karen K; Papamargaritis. Dimitris D
Key Findings
- Tirzepatide users had a non‑significant 16% lower risk of overall obesity‑associated cancers versus DPP‑4 inhibitors (HR 0.84, 95% CI 0.69‑1.01).
- A significant 69% reduction in ovarian cancer risk was observed with tirzepatide (HR 0.31, 95% CI 0.10‑0.95).
- Other weight‑loss interventions (semaglutide, bariatric surgery) showed clearer cancer‑risk reductions, suggesting the benefit may be tied to the amount of weight loss.
Practical Outcomes
- For biohackers considering tirzepatide for weight loss, the drug appears safe and may offer some extra cancer‑protective edge, especially for ovarian cancer, but the overall cancer benefit isn’t proven yet. Pairing tirzepatide with strong lifestyle changes (diet, exercise) is likely needed to maximize any protective effect. Monitor health markers regularly and discuss cancer‑risk expectations with a healthcare professional before starting.
Summary
In a large real‑world study, people with type‑2 diabetes who were overweight or obese and took tirzepatide lost weight and showed a trend toward fewer obesity‑related cancers compared with those on older diabetes pills, though the overall cancer reduction wasn’t statistically solid. The only clear cancer benefit was a much lower chance of ovarian cancer.
Abstract
To evaluate whether weight-loss interventions are associated with obesity-associated cancers (OAC) in individuals with overweight/obesity and type 2 diabetes (T2D). This retrospective cohort study utilised the TriNetX federated research network. Three cohorts of adults with overweight/obesity and T2D, treated with either semaglutide, tirzepatide or bariatric surgery (BS) between June 2005 and June 2025, were propensity score matched (1:1) to cohorts treated with dipeptidyl peptidase-4 inhibitors (DPP-4i) using potential confounding factors. Using Cox regression analysis, we estimated hazard ratios (HRs) of composite and individual OAC: breast, colorectal, gallbladder, liver, multiple myeloma, oesophageal, ovarian, pancreatic, renal, gastric cardia, thyroid and uterine cancers. In 64,178 matched pairs (mean follow-up 911 days), semaglutide (vs. DPP-4i) was associated with lower rates of composite OAC (HR: 0.88; 95% CI: 0.82-0.95), colorectal (0.80; 0.67-0.97), liver (0.75; 0.60-0.95) and pancreatic (0.76; 0.60-0.96) cancers. In 19,682 matched pairs (mean follow-up 435 days), tirzepatide (vs. DPP-4i) was associated with a non-significant lower rate of composite OAC (0.84; 0.69-1.01) but a significant lower rate of ovarian cancer (0.31; 0.10-0.95). In 9642 matched pairs (mean follow-up 1746 days), BS (vs. DPP-4i) was associated with lower rates of composite OAC (0.85; 0.74-0.98), liver (0.56; 0.32-0.97) and uterine cancers (0.59; 0.38-0.90), and higher rates of gastric cardia cancer (10.54; 1.35-82.38) and oesophageal cancer (4.78; 1.04-21.87). Semaglutide and BS were associated with lower cancer rates in individuals with overweight/obesity and T2D, with non-significant lower rates also observed with tirzepatide. These findings suggest weight-loss interventions may contribute to cancer prevention in this population.
Study Information
pubmed
2025
2025-09-03T00:00:00.000Z
10.1111/dom.70090
1
60